Plans to increase uptake of biosimilars could save £300m from NHS drugs bill

Plans to increase uptake of biosimilars could save £300m from NHS drugs bill

September 20 2017 The NHS is set to encourage greater uptake of biosimilar medicines in an...

RPS developing polypharmacy guidance

RPS developing polypharmacy guidance

August 31 2017 The Royal Pharmaceutical Society has commenced a year-long programme to develop...

Scotland sets out next stage of its long-term pharmacy strategy

Scotland sets out next stage of its long-term pharmacy strategy

August 22 2017 Scotland has a new pharmacy strategy, ‘Achieving Excellence in...

ICO warns about unlawfully accessing patient records

ICO warns about unlawfully accessing patient records

August 15 2017People handling patient records must have a valid reason to access the information...

NHS Alliance calls for better recognition of clinical pharmacist role in ‘high street pharmacy’

NHS Alliance calls for better recognition of clinical pharmacist role in ‘high street pharmacy’

June 29 2016 The NHS should support clinical pharmacist roles in community pharmacies as well as...

  • Plans to increase uptake of biosimilars could save £300m from NHS drugs bill

    Plans to increase uptake of biosimilars could save £300m from NHS drugs bill

    Wednesday, 20 September 2017 13:55
  • RPS developing polypharmacy guidance

    RPS developing polypharmacy guidance

    Thursday, 31 August 2017 12:47
  • Scotland sets out next stage of its long-term pharmacy strategy

    Scotland sets out next stage of its long-term pharmacy strategy

    Tuesday, 22 August 2017 11:49
  • ICO warns about unlawfully accessing patient records

    ICO warns about unlawfully accessing patient records

    Tuesday, 15 August 2017 18:06
  • NHS Alliance calls for better recognition of clinical pharmacist role in ‘high street pharmacy’

    NHS Alliance calls for better recognition of clinical pharmacist role in ‘high street pharmacy’

    Wednesday, 29 June 2016 11:46

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

pills4June 27 2016

Guidance on naloxone supply has been updated with advice about what to consider when there is a need for use in people under 18 years.

The guidelines were introduced in October 2015 as part of a move to widen the availability of naloxone as an emergency antidote for overdoses caused by heroin and other opiates or opioids such as methadone and morphine.

They are intended for use by drug treatment services authorised to supply naloxone, including:

  • drug services commissioned from primary care providers
  • drug services commissioned from secondary care providers (including a range of specialised community and inpatient drug services)
  • commissioned services providing needle and syringe programmes (including those provided from pharmacies)
  • pharmacies providing drug treatment services.

The update says that “any drug treatment service considering providing a child or young person under 18 with training on overdose management or on the use of naloxone, or considering direct supply of naloxone, should always act in line with established clinical principles for the treatment of children and young people.

“This is the case whether the goal of such consideration is to reduce risks to a young person who is using drugs or to reduce risk for others (such as an opioid-using parent).”

It points out that there are no legal restrictions under the 2015 legislation, and that “such a decision would need very careful consideration and oversight and would need to be made on a case by case basis.

“An appropriately competent professional acting within a suitable clinical governance framework would have to consider the needs of each child or young person, taking account of potential benefits to the child of the intervention and any risks.”

Factors they would need to take into account include the child or young person’s ability to understand the issues involved and to provide suitable consent. “In the case of a child who exercises a carer role for a drug-using parent, consideration of the interests of the child can be quite complex.” There is also a need to consider issues such as those relating to child safeguarding.

Links:

Department of Health Guidance

Updated guidance

Legal & Policy News

September 21 2017 Pharmacy IT systems supplier Cegedim has announced it has commenced beta testing of Pharmacy Manager version 10.3. The new version has specific functionalities for England and...
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...